Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EXPERIENCE IN THE USE OF BISOPROLOL IN THE TREATMENT OF OUTPATIENT HYPERTENSIVE PATIENTS AFTER STROKE

https://doi.org/10.20996/1819-6446-2014-10-4-421-424

Full Text:

Abstract

Aim. To study the dynamics of blood pressure (BP), heart rate (HR), the sympathetic-vagal balance in patients with arterial hypertension (HT) III stage after stroke during therapy based on bisoprolol 5-10 mg/day.

Material and methods. Patients (n=12) with HT stage III with stroke history were examined. Age of the patients was 62±7.4 years old. Laboratory tests, BP monitoring, evaluation of the ratio of low frequency (LF) and high frequency (HF) components of HR variability and average daily HR determination were performed in all patients at baseline, after 14 and 34 days after therapy initiation. Bisoprolol was administered at dose of 5-10 mg/day.

Results. BP decreased to the target level in all patients after 14 days of treatment and persisted through 34 days. Average daily HR and LF/HF ratio decreased, reaching the optimal values after 34 days. Significant dynamics in metabolic parameters and side effects were not found.

Conclusion. Target BP levels, a significant decrease in HR and sympathetic activity, increase in parasympathetic activity of the autonomic regulation occurred since 14-th day of therapy based on bisoprolol (5-10 mg/day). The received effects allowed patients to continue rehabilitation therapy, accompanied with physical exertion.

About the Authors

I. I. Esenova
City clinic №62 of Moscow Health Department, Branch №2
Russian Federation
Unnatov ul. 12, Moscow, 125083 Russia


L. N. Lisenker
City clinic №62 of Moscow Health Department, Branch №2
Russian Federation
Unnatov ul. 12, Moscow, 125083 Russia


References

1. Schunemann H.J., Oxman A.D., Brozek J. et al. Gradin g quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336:1106-10.

2. Duplyakov DV, Popova IV. Rosuvastatin in the primary and secondary prevention of cardiovascular disease. Attending Physician 2012; (2): 29-31. Russian (Дупляков Д.В., Попова И.В. Розувастатин в первичной и вторичной профилактике сердечно-сосудистых заболеваний. Лечащий Врач 2012; (2): 29-31).

3. Lupanov VP. Combination therapy in patients with ischemic heart disease and hypertension. Attending Physician 2007; (3): 19-25. Russian (Лупанов В.П. Комбинированная терапия больных ишемической болезнью сердца и артериальной гипертензией. Лечащий врач 2007; (3): 19-25).

4. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

5. National guidelines for the diagnosis and treatment of hypertension (4th revision) . Sistemnie Gypertensii 2010 (3): 5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26).

6. Palatini P. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs. Drugs 1999; 57: 713-24.

7. CIBIS II Investigators and committers. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet 1999; 353: 9-13.

8. Britov AN. Role cardioselective ß-blocker (bisoprolol) in the treatment of patients with arterial hypertension associated with heart failure. Cardiovascular Therapy and Prevention 2005; 3: 104-10. Russian (Бритов А.Н. Роль кардиоселективного ß-адреноблокатора (бисопролола) в лечении больных артериальной гипертонией, ассоциированной с сердечной недостаточностью. Кардиоваскулярная Терапия и Профилактика 2005; 3: 104-10).

9. Lukina YuV, Martsevich SYu. Bisoprolol is highly selective beta-blocker with evidence-based medicine. Ration Pharmacother Cardiol 2010; 6 (1): 103-7. Russian (Лукина Ю.В., Марцевич С.Ю. Бисопролол – высокоселективный бета-адреноблокатор с позиции доказательной медицины. Рациональная Фармакотерапия в Кардиологии 2010; 6(1): 103-7).

10. The efficacy and safety of drug therapy for primary and secondary prevention of cardiovascular disease. National Guidelines. Ration Pharmacother Cardiol 2011; 7 (5): 2-72. Russian (Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечнососудистых заболеваний. Национальные Рекомендации. Рациональная Фармакотерапия в Кардиологии 2011; 7(5): 2-72).

11. Maggioni A.P., Sinagra G., Opasich C. et al. Beta blockers in patients with congestive heart failure: guided use in clinical practice Investigators. Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. Heart 2003; 89(3): 299-305.

12. Shalnova SA, Deev AD, Oganov RG et al. Heart rate and mortality from cardiovascular diseases in Russian men and women. Results of an epidemiological study. Cardiology 2005; (10): 45-50. Russian (Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; (10): 45-50).

13. Shilov AM. Beta-blocker of the second generation in the practice of the treatment of hypertension. Farmateka 2008; (8): 44-6. Russian (Шилов А.М. Бета-блокатор второго поколения в практике лечения артериальной гипертонии. Фарматека 2008; (8): 44-6).

14. Owada A, Suda S, Hata T, et al. The effect of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens 2001;23: 305-16.


For citation:


Esenova I.I., Lisenker L.N. EXPERIENCE IN THE USE OF BISOPROLOL IN THE TREATMENT OF OUTPATIENT HYPERTENSIVE PATIENTS AFTER STROKE. Rational Pharmacotherapy in Cardiology. 2014;10(4):421-424. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-4-421-424

Views: 456


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)